A Columbia University study finds that combining plasma p-tau217 blood tests with APOE4 genotyping can predict Alzheimer’s symptom onset within three to four years in high-risk, asymptomatic individuals.
5Q Spectra plans to launch the Prostate Dx blood test, designed to help assess prostate cancer risk after elevated PSA results and potentially reduce unnecessary biopsies.
A University of Washington study found the panel cross-reacts with 78 gut bacteria species, resulting in over 250,000 false-positive norovirus results since 2019.
FDA clearance of the BD Onclarity Self-Collection Kit in April 2026 enables at-home HPV testing for cervical cancer screening, expanding access and addressing barriers for under-screened populations.
A study found that use of IBS-Smart and Trio-Smart tests was linked to fewer colonoscopies and lower diagnostic costs among adults with suspected irritable bowel syndrome.
Exome sequencing identified genetic causes in 12% of unexplained premature ovarian insufficiency cases, according to University of Tartu researchers, highlighting potential for broader genetic testing.
A Vanderbilt study finds that standard genetic tests for lamotrigine reaction risk omit HLA-A*32:01, a marker linked to severe DRESS, raising concerns about current pharmacogenomic panel effectiveness.
Labcorp has announced the upcoming launch of the Marker by Labcorp Genetic Health Panel, which will analyze 163 genes linked to over 100 medically actionable conditions, with results supported by licensed genetic counselors.
Seed Healthcare has led a strategic investment in Diadem to support US commercialization of AlzoSure Predict, a blood-based Alzheimer’s diagnostic recently validated in over 900 patients and designated a Breakthrough Device by the FDA.
A University of Exeter study finds that adding a genetic risk score to MODY testing can identify hidden type 1 diabetes in 16% of patients with negative genetic results, supporting updated NHS diagnostic protocols.
A Johns Hopkins study reports that adding three urine biomarkers to standard assessments raises the accuracy of predicting deceased donor kidney transplant success from 80% to 86%.
The Cystic Fibrosis Base assay has received IVDR accreditation, ensuring high standards for detecting cystic fibrosis mutations.
A study validates Nu.Q NETs H3.1 nucleosomes as independent predictors of 28-day mortality and renal replacement therapy need in sepsis and septic shock, according to VolitionRx.